Patents by Inventor Virginie Baylot

Virginie Baylot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINED ANTI-CYTOKINE THERAPY TO REDUCE METASTATIC CANCER
    Publication number: 20230109697
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal.
    Type: Application
    Filed: January 13, 2021
    Publication date: April 13, 2023
    Inventors: Virginie Baylot, Renumathy Dhanasekaran, Dean W. Felsher
  • Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
    Patent number: 10105384
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: October 23, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II
    Inventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou
  • NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS
    Publication number: 20150216891
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Applicants: Institut National De La Sante Et De La Recherche Medicale (Inserm), UNIVERSITE DE LA MEDITARRANEE AIX-MARSEILLE II
    Inventors: Palma ROCCHI, Virginie BAYLOT, Julie ACUNZO, Claudia ANDRIEU, Maria KATSOGIANNOU
  • Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
    Patent number: 9034840
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: May 19, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de la Mediterrance Aix-Marseille II
    Inventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou
  • NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS
    Publication number: 20130266572
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 10, 2013
    Applicant: UNIVERSITE DE LA MEDITARRANEE AIX-MARSEILLE II
    Inventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou